title: [Incidence of graft rejection after pancreas and kidney transplantation].
abstract: The possibility of an immunological follow-up of the pancreas through the renal transplant after simultaneous pancreaticorenal transplantation (S.P.R.T.) is controversial. Fifty patients have received a neopren-injected extraperitoneal segmental pancreatic transplant and a contralateral renal transplant, after immunological preparation with blood transfusions, without tissue matching but with a negative anti-T lymphocyte cross-match. Immunosuppression consisted in a three- or four-drug therapy during the first 10 days, then a long-term two-drug therapy (ciclosporine and azathioprine). Sixteen rejection episodes were noted in 16 patients during the first 3 postoperative months. No concomitant alteration of the pancreatic function occurred (no pancreatic histology). No isolated pancreatic rejection has been noted so far. One patients presented with 2 episodes of simultaneous rejection 15 and 26 months after transplantation. The actuarial survival rate at 2 years of the patients, kidneys and pancreata respectively is 96%, 92% and 80%. The absence of long-term alteration of the pancreatic function probably proves the absence of undetected pancreatic rejection. In our experience, the follow-up of the renal function allows screening and treating rejection episodes before a possible functional alteration of the pancreatic transplant occurs. In our opinion, extraperitoneal segmental pancreatic transplantation, a simple procedure with satisfactory metabolic results in the long term, is a good technique for S.P.R.T.
authors.affiliation: Clinique chirurgicale, Centre hospitalier et universitaire de Nantes.
authors.forename: J
authors.initials: J
authors.lastname: Paineau
authors.forename: D
authors.initials: D
authors.lastname: Cantarovich
authors.forename: J P
authors.initials: JP
authors.lastname: Couderc
authors.forename: E
authors.initials: E
authors.lastname: Letessier
authors.forename: O
authors.initials: O
authors.lastname: Bouchot
authors.forename: G
authors.initials: G
authors.lastname: Karam
authors.forename: J P
authors.initials: JP
authors.lastname: Soulillou
authors.forename: J
authors.initials: J
authors.lastname: Visset
mesh_terms: D000206:Actuarial Analysis; D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D003920:Diabetes Mellitus / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D015994:Incidence; D007328:Insulin / Q000097:blood; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D016035:Pancreas Transplantation / Q000009:adverse effects*
chemical_list: D001786:Blood Glucose; D007328:Insulin
vernacular_title: Incidence du rejet après transplantation pancréatico-rénale.